DalsnaFinance › IPOs › ADARx Pharmaceuticals › IPO
ADARx Pharmaceuticals, Inc. completed its initial public offering on Nasdaq on September 22, 2026, pricing at $17.00 a share.
| Ticker | ADRX |
|---|---|
| Exchange | Nasdaq |
| Status | Completed |
| Listing date | September 22, 2026 |
| Offering price | $17.00 |
| Shares offered | 26,250,000 |
| Total raised | $446M |
| Sector | Pharmaceutical Preparations |
ADARx Pharmaceuticals, Inc. listed on Nasdaq on 2026-09-22.
Ingested from SEC EDGAR (424B4, 8-A12B), CIK 1802369.
ADARx Pharmaceuticals, Inc. sold 26,250,000 shares at $17.00 each on Nasdaq. Multiplied out, that is $446.3 million in gross proceeds, the figure before underwriting discounts and offering expenses, and it agrees with the $446 million total recorded for the deal.
Measured by money raised, ADARx Pharmaceuticals, Inc. was the 53rd largest of 475 completed IPOs with a recorded deal size that this site tracks since October 8, 2024. The median deal in the same window raised $200 million, so this one was about 2.2 times the typical size.
Among the 7 listings on Nasdaq alone, it is the 3rd largest.
Its $17.00 offer price was tied for the 97th highest (level with 13 other listings) of the 488 listings in the window with a recorded price. A share price on its own says nothing about a company's value; it depends on how many shares exist.
ADARx Pharmaceuticals, Inc. — quote, profile and latest news →
Source: SEC EDGAR filings for ADARx Pharmaceuticals, Inc.. This page is general information, not investment advice.